Show simple item record

dc.contributor.editorSchnebly, Risa Ariaen_US
dc.creatorDarby, Alexisen_US
dc.creatorJones, Sierra Hopeen_US
dc.date.accessioned2021-03-01T18:23:41Zen_US
dc.date.available2021-03-01T18:23:41Zen_US
dc.date.created2021-03-01en_US
dc.identifier.urihttps://hpsrepository.asu.edu/handle/10776/13231en_US
dc.description.abstractTo address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens between 2010 and 2012 specifically for HIV-positive pregnant women and their infants. WHO developed the regimens, calling them Option A, Option B, and Option B+, to reduce or prevent mother-to-child, abbreviated MTC, transmission of HIV. Each option comprises of different types and schedules of antiretroviral medications. As of 2018, WHO reported that in Africa alone about 1,200,000 pregnant women were living with untreated HIV. Those women have up to a forty-five percent chance of transmitting HIV to their offspring if they do not receive treatment. Option B+ has decreased the overall maternal mortality rates in many low- and middle-income countries, and numerous studies have supported the notion that it is the most effective of the three regimens for preventing MTC transmission of HIV.en_US
dc.format.mediumtext/xhtmlen_US
dc.language.isoen_USen_US
dc.language.isoen_USen_US
dc.publisherArizona State University. School of Life Sciences. Center for Biology and Society. Embryo Project Encyclopedia.en_US
dc.relation.ispartofEmbryo Project Encyclopediaen_US
dc.rightsCopyright Arizona Board of Regentsen_US
dc.subjectConcepten_US
dc.subject.lcshHIV-positive personsen_US
dc.subject.lcshHIV infectionsen_US
dc.subject.lcshHIV-positive youthen_US
dc.subject.lcshHIV-positive womenen_US
dc.subject.lcshHIV-positive childrenen_US
dc.subject.lcshARV (Viruses)en_US
dc.subject.lcshHIV infections--Treatmenten_US
dc.subject.lcshHIV infections--Complicationsen_US
dc.subject.lcshHIV-positive persons--Care--Handbooks, manuals, etcen_US
dc.subject.lcshHIV infections--Africaen_US
dc.subject.meshHIV Infectionsen_US
dc.subject.meshHIV Seroconversionen_US
dc.subject.meshHuman Immunodeficiency Virus Proteinsen_US
dc.subject.meshAnti-HIV Drugsen_US
dc.subject.meshHighly Active Antiretroviral Therapyen_US
dc.subject.meshAntiretroviral Agentsen_US
dc.subject.meshHIV-Related Opportunistic Infectionsen_US
dc.subject.meshAIDS-Related Opportunistic Infectionsen_US
dc.subject.meshHIV Receptorsen_US
dc.subject.meshHIV-1en_US
dc.subject.meshHIV Serodiagnosisen_US
dc.subject.meshHIV Antigensen_US
dc.subject.meshHIV-Associated Antibodiesen_US
dc.subject.meshHIVen_US
dc.subject.meshHuman Immunodeficiency Virusen_US
dc.subject.meshVirus, Human Immunodeficiencyen_US
dc.subject.meshFetomaternal Infection Transmissionen_US
dc.subject.meshInfectious Disease Transmission, Verticalen_US
dc.subject.meshMother-to-Child Transmissionen_US
dc.titleWorld Health Organization Guidelines (Option A, B, and B+) for Antiretroviral Drugs to Treat Pregnant Women and Prevent HIV Infection in Infantsen_US
dc.typeArticleen_US
dc.typeTexten_US
dc.rights.licenseLicensed as Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported (CC BY-NC-SA 3.0) http://creativecommons.org/licenses/by-nc-sa/3.0/en_US
dc.subject.embryoReproductionen_US
dc.subject.embryoProcessesen_US
dc.subject.embryoDisordersen_US
dc.subject.tagHIV treatmenten_US
dc.subject.tagmother-to-child HIV transmissionen_US
dc.subject.tagHIV drug resistanceen_US
dc.subject.tagWorld Health Organizationen_US
dc.description.typeArticlesen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record